Prof. Raymond Comenzo (Tufts University, USA) presented 1-year follow-up data from the phase 3 ANDROMEDA trial; the combination of subcutaneous daratumumab with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) led to high overall and complete response (CR) rates in patients with newly diagnosed amyloid light chain (AL) amyloidosis.
In the safety run-in single arm phase of ANDROMEDA, 28 patients (median age 68 years; range 35-83 years) with previously untreated AL amyloidosis received daratumumab 1,800 mg (formulated with recombinant human hyaluronidase PH20) administered subcutaneously once a week during cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks thereafter for up to 2 years. Patients also received CyBorD, with cyclophosphamide 300 mg/m2, bortezomib 1.3 mg/m2, and dexamethasone 40 mg, administered once weekly for up to 6 treatment cycles. Researchers followed patients for a median of 341 days (r...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Obinutuzumab/polatuzumab in follicular lymphoma Next Article
Early trial data shows positive results for treating anaemia in patients with end-stage renal failure »
Table of Contents: EHA 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.